BMY vs NUVB: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
BMY is the larger of the two ($122.05B market cap): the incumbent the market prices for continued execution (9.04x forward earnings, beta 0.18). NUVB is the smaller challenger ($1.56B), priced similarly on forward earnings (-296.67x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BMY vs NUVB: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BMY | NUVB | What it tells you |
|---|---|---|---|
| Market cap | $122.05B | $1.56B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 9.04 | -296.67 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.18 | 1.62 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 66% of range | 17% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.47 | 6.13 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how BMY and NUVB affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and NUVB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and NUVB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Bristol Myers Squibb (BMY) do?
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is working through a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.
What does Nuvation Bio (NUVB) do?
Nuvation Bio (NYSE: NUVB) is a San Francisco oncology company founded by David Hung, best known for previously building and selling Medivation. Its commercial anchor is IBTROZI (taletrectinib), a next-generation oral ROS1 tyrosine kinase inhibitor that received full FDA approval in June 2025 for locally advanced or metastatic ROS1-positive non-small cell lung cancer across lines of therapy. The drug is positioned against first-generation options like Pfizer's Xalkori and Roche's Rozlytrek and the newer Bristol Myers Squibb agent Augtyro, and it has been added as a preferred option in NCCN guidelines. On September 17, 2026, about four months ahead of its target date, the FDA approved a supplemental application that adds a median duration of response of 49.7 months in TKI-naive patients from the TRUST-I study, which the company calls the longest reported for an FDA-approved ROS1 TKI, with no new safety signals. Beyond IBTROZI, the pipeline includes safusidenib (a brain-penetrant IDH1 inhibitor), NUV-1511 (a drug-drug conjugate), and NUV-868 (a BET inhibitor).
BMY vs NUVB: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BMY drivers: New product portfolio ramp; Oncology and immunology depth.
- NUVB drivers: IBTROZI commercial ramp; Global partner economics.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For NUVB, iBTROZI targets a relatively small ROS1-positive niche, so peak sales are inherently capped and depend on diagnostic testing rates and competition from Roche's Rozlytrek and BMS's Augtyro.
BMY or NUVB: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; NUVB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and NUVB guides.
BMY vs NUVB: the full fundamentals
BMY. At about $60.80 on October 16, 2026, Bristol Myers trades near 9 times forward earnings, still low relative to large-cap pharma peers, which reflects market skepticism about replacing patent-cliff revenue even after a 40% one-year rally. The 4.2% dividend yield and strong cash flow are the bull-case anchors, while consensus for roughly flat 2027 EPS (about $6.62 versus $6.65 for 2026) captures the bear case. The 24 analysts in Yahoo's consensus carry a mean target near $66, and Q3 2026 results arrive on October 29.
NUVB. Reported TTM revenue is inflated by large one-time collaboration upfronts, so quarterly revenue in the $30 million range (Q2 2026) is a more conservative gauge of the commercial base. With about $661 million in cash against about $416 million of debt and a market capitalization near $1.6 billion, the valuation largely reflects expectations for future IBTROZI growth and royalty streams rather than current recurring sales. Analysts expect losses to narrow toward breakeven in 2027 (consensus EPS about -$0.01), and the average price target across 11 analysts was about $13.
Headline figures (approximate, October 2026): BMY shows revenue (ttm) ~$49.2 billion (Q2 2026 up ~5.7% YoY), q2 2026 adjusted eps $2.04 vs $1.60 consensus, operating margin ~34%, net income (ttm) ~$9.3 billion; NUVB shows market cap ~$1.6B, share price (oct 16, 2026) ~$4.56, revenue (ttm) ~$170M (boosted by one-time license upfronts), q2 2026 total revenue ~$32M.
The bottom line: BMY vs NUVB
BMY and NUVB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and NUVB exposure against your real portfolio. It is not an investment adviser.
Wondering how BMY or NUVB fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Bristol Myers Squibb with AI
Connect the broker you already use and ask Walnut's AI how BMY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between BMY and NUVB?
+
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Nuvation Bio (NYSE: NUVB) is a San Francisco oncology company founded by David Hung, best known for previously building and selling Medivation. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BMY or NUVB the better stock?
+
Neither is universally better. BMY is the larger incumbent; NUVB is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BMY or NUVB?
+
On forward P/E (as of October 2026), BMY trades at 9.04x and NUVB at -296.67x, so NUVB is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BMY and NUVB?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BMY vs NUVB?
+
BMY: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed, and consensus already pencils in flat to lower revenue and EPS in 2027. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook; the split admilparant readout in October 2026, which also came with protocol changes and a patient death the company said was likely unrelated, is a reminder of how quickly pipeline news can move the stock. Debt of about $45 billion against about $11 billion of cash, and litigation exposure, add further uncertainty. NUVB: IBTROZI targets a relatively small ROS1-positive niche, so peak sales are inherently capped and depend on diagnostic testing rates and competition from Roche's Rozlytrek and BMS's Augtyro. Reported profitability in Q1 2026 was flattered by a one-time Eisai upfront, and Q2 2026 swung back to a net loss of about $63 million, so recurring product revenue is still small relative to a market capitalization around $1.6 billion. The balance sheet carries about $416 million of debt alongside roughly $661 million of cash, and free cash flow was about -$112 million over the trailing twelve months. The company has issued equity (a 2026 shelf/offering) and could dilute further, and much of the pipeline beyond taletrectinib is early-stage with binary trial and regulatory outcomes. As a single-product commercial company, any launch stumble, pricing pressure, or safety signal would weigh heavily on the shares, which fell about 29% over the three months to October 16, 2026.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BMY or NUVB; figures are approximate and dated (as of October 2026). Verify current data before investing.